ライフサイエンスコーパス: octreotide

1 r (111)In-diethylenetriaminepentaacetic acid-octreotide.

2 t (111)In-diethylenetriaminepentaacetic acid-octreotide.

3 h (111)In-diethylenetriaminepentaacetic acid-octreotide.

4 lso appears to be more accurate than (111)In-octreotide.

5 dium-chain triglyceride supplementation, and octreotide.

6 were put on total parenteral nutrition plus octreotide.

7 adjuvant trial of tamoxifen with or without octreotide.

8 ed with historical controls not treated with octreotide.

9 on in a dose-dependent manner, comparable to octreotide.

10 symptoms were worse in patients treated with octreotide.

11 ncies (IC(50), 0.1-1.0 microM) comparable to octreotide.

12 tion-approved radiopharmaceutical indium 111 octreotide.

13 a dose-dependent manner by administration of octreotide.

14 hose developing in acromegalics treated with octreotide.

15 r (111)In-diethylenetriaminepentaacetic acid-octreotide.

16 c meeting abstracts, and the manufacturer of octreotide.

17 onstriction was significantly potentiated by octreotide.

18 denectomy and found no benefit to the use of octreotide.

19 s to many more sst2 sites than (125)I-Tyr(3)-octreotide.

20 atively stable somatostatin analogs, such as octreotide.

21 ng (68)Ga-DOTATATE to be more sensitive than octreotide.

22 er injection of 111-185 MBq of (99m)Tc-HYNIC-octreotide.

23 Patients received octreotide 0.5 mg subcutaneously tid.

24 o (4.17, 1.37-12.50) and over midodrine plus octreotide (10.00, 1.49-50.00) for this outcome.

25 located in a double-blind fashion to receive octreotide (100 microg, administered subcutaneously on d

26 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing

27 n-labeled diethylenetriaminepentaacetic acid-octreotide ((111)In-DTPA-OC).

28 h a single radioligand, either (125)I-Tyr(3)-octreotide, (125)I-GLP-1(7-36)amide, or (125)I-GIP(1-30)

29 agement in 51%); and comparison with (111)In-octreotide (2 papers, sensitivity of DOTATOC on a per-le

30 ne 4 microg/min; octreotide 20 microg/h, and octreotide 20 microg/h + methacholine 4 microg/min.

31 ere administered: methacholine 4 microg/min; octreotide 20 microg/h, and octreotide 20 microg/h + met

32 d subcutaneously on day 1, followed by depot octreotide, 20 mg, administered intramuscularly on days

33 istorical control group that did not receive octreotide (24% versus 43%; P=0.04).

34 ic controls, (2) acromegalics untreated with octreotide, (3) acromegalics on long-term octreotide, an

35 glucagon, we infused the somatostatin analog octreotide (30 ng x kg(-1) x min(-1)) (with growth hormo

36 mg per kilogram of body weight per day) and octreotide (35 mug per kilogram per day).

37 zacyclotetradecane-1,4,8,11-tetraacetic acid-octreotide ((64)Cu-TETA-OC) and (111)In-labeled diethyle

38 r PET tracers such as [(68)Ga-DOTA,1-Nal(3)]-octreotide ((68)Ga-DOTANOC) and [(68)Ga-DOTA,Tyr(3)]-oct

39 , (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in

40 with PLE included spironolactone (21 [68%]), octreotide (7 [21%]), sildenafil (6 [19%]), fenestration

41 Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and

42 acyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or with cycles alternating

43 d, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue.

44 Octreotide, a somatostatin analog, is proposed to reduce

45 onary effects of serotonin and bradykinin is octreotide, a somatostatin analogue.

46 Proof of principle studies with octreotide, a somatostatin receptor agonist, demonstrate

47 Finally, octreotide abrogated the activation of phosphorylation o

48 s incubated with GH and SRIF, or with GH and octreotide, abrogated the inhibitory effect on GH-induce

49 ed either 1 mL 0.9% saline or 1 mL (100 mug) octreotide acetate subcutaneously followed by a standard

50 After octreotide, ad libitum calorie intake increased among ES

51 a hospitalization for GI bleed and received octreotide after discharge.

52 i-inflammatory and anti-apoptotic effects of octreotide after HIR.

53 ents who received secondary prophylaxis with octreotide after their index GI bleed from 2009 to 2015.

54 Moreover, octreotide alleviated inflammation and apoptosis in the

55 Octreotide alone has modest activity in patients with oc

56 Responding patients continued to receive octreotide alone; patients with progressive disease were

57 ) were observed (four partial responses with octreotide alone; the remainder with octreotide plus pre

58 Octreotide also inhibited GH-stimulated IGF-I protein co

59 r interferon alfa-2b (IFN-alpha-2b) added to octreotide among patients with advanced NETs.

60 Thus, we assessed cAMP levels and evaluated octreotide (an analogue of somatostatin known to inhibit

61 Octreotide, an SSTR agonist, has been used to suppress t

62 Recently, (57)Co-labeled DOTATOC, an octreotide analog, was shown to have the highest affinit

63 Radiolabeled octreotide analogs are most successfully being applied t

64 the biologic effects of novel cobalt-labeled octreotide analogs targeting the somatostatin receptor t

65 No direct comparison of octreotide and (68)Ga-DOTATATE imaging for diagnosis and

66 in analogue that has a longer half-life than octreotide and a broader binding profile, decreases panc

67 nt continues to be treated successfully with octreotide and amlodipine.

68 TATATE for safety and efficacy compared with octreotide and conventional imaging to determine whether

69 d staging of NETs compared with (111)In-DTPA-octreotide and conventional imaging.

70 Octreotide and lanreotide are further being described fo

71 Micromolar concentrations of octreotide and NISAs are necessary for antiangiogenic ef

72 Use of octreotide and seeking specialist advice early for patie

73 Octreotide and somatostatin-28 cell membrane binding aff

74 onists and multireceptor agonists, including octreotide and somatostatin-28.

75 of liver cysts in mice treated with combined octreotide and sorafenib.

76 iscovery of the antiangiogenic properties of octreotide and the overexpression of tyrosine kinase rec

77 th octreotide, (3) acromegalics on long-term octreotide, and (4) patients with constipation.

78 specificity, comparison studies with (111)In-octreotide, and change of management studies.

79 ted the use of noradrenaline, midodrine plus octreotide, and dopamine plus furosemide over placebo to

80 de, interferon alpha-2b, letrozole, Y-27632, octreotide, and human growth hormone, all delivered at c

81 oduce the effects of the drugs verapamil and octreotide, and we show that the experimental CF drug VX

82 in 18%, 31%, 31%, and 21% of patients in the octreotide arm, respectively, and in 25%, 32%, 22%, and

83 Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usa

84 e tested for the cumulative dose-response to octreotide at baseline conditions and after preconstrict

85 ansfer in tumor-bearing animals with (111)In-octreotide at doses similar to those already used in hum

86 ved pazopanib 800 mg orally once per day and octreotide at their preprotocol dosage.

87 lso a significant reduction in the amount of octreotide being used after completion of (90)Y-SMT 487

88 oendocrine tumors from patients treated with octreotide but that a striking variability exists in the

89 ive uptake studies showed that blocking with octreotide caused a dose-dependent reduction in (64)Cu-M

90 ment, suppression of glucagon secretion with octreotide caused a progressive fall in plasma glucose c

91 als are underway to evaluate the efficacy of octreotide, celecoxib, and candesartan on DR.

92 wley rats were pretreated with octreotide or octreotide combined with 3-methyladenine (autophagy inhi

93 Octreotide combined with emodin or 4,5,6,7-tetrabromoben

94 using either the anti-HA antibody or (111)In-octreotide correlated with biodistribution and imaging s

95 onships of a series of rhenium (Re)-cyclized octreotide derivatives are described.

96 nsitivity of PET imaging with (68)Ga-labeled octreotide derivatives for the detection and staging of

97 Re-cyclization of the octreotide derivatives led to structural perturbations o

98 (111)In-Octreotide detected the SSTR2 portion of the fusion prot

99 Octreotide did not affect baseline perfusion pressures (

100 As administered in this study, octreotide did not decrease diarrhea during pelvic radia

101 e that the prophylactic use of perioperative octreotide does not reduce the incidence of pancreatic f

102 ric anastomosis, received appropriate saline/octreotide doses, and were available for endpoint analys

103 receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual

104 lguanidine (MIBG) and (90)Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic

105 in, [Tyr(4)]-neurotensin(8-13), and [Tyr(3)]-octreotide, each of which has a different position for t

106 his indicates that in preprandial conditions octreotide enhances the vasoconstrictive effect of depen

107 rs involving activation of protein kinase C, octreotide exerts a local vasoconstrictive effect on vas

108 Octreotide exerts a protective effect in hepatic ischemi

109 Octreotide exhibits an integrated effect of both recepto

110 Acute or chronic octreotide exposure at low or high doses did not signifi

111 ents with negative or equivocal (111)In-DTPA-octreotide findings, (68)Ga-DOTATATE PET identifies addi

112 ro exposure of cells to low or high doses of octreotide for 1-14 d does not result in the development

113 Both donors and recipients were treated with octreotide for 5 days perioperatively.

114 transfected cells were injected with (111)In-octreotide for biodistribution and imaging studies.

115 rials to evaluate the safety and efficacy of octreotide for esophageal variceal hemorrhage.

116 We identified randomized trials of octreotide for variceal hemorrhage from computerized dat

117 of novel medical treatments (eg, long-acting octreotide formulations, mTOR inhibitors, and GLP-1 rece

118 oncentration during a 180-minute infusion of octreotide, glucose, and insulin was used to stratify pa

119 concentration in response to an infusion of octreotide, glucose, and insulin, and degree of adiposit

120 ing the last 30 min of a 180-min infusion of octreotide, glucose, and insulin.

121 ractically unchanged (+0.25%+/-7.53%) in the octreotide group but increased by 8.61%+/-10.07% in the

122 ver volume decreased by 4.95%+/-6.77% in the octreotide group but remained practically unchanged (+0.

123 patient-reported symptoms were worse in the octreotide group, including nocturnal bowel movements (7

124 were 9% in the control group and 11% in the octreotide group.

125 were 34% in the control group and 40% in the octreotide group; the in-hospital death rates were 0% ve

126 device receiving secondary prophylaxis with octreotide had a significantly lower GI bleed recurrence

127 Octreotide had comparable efficacy to immediate scleroth

128 Although octreotide had similar inhibiting potency (picomolar) fo

129 ian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activi

130 pecific therapy with somatostatin analogues (octreotide) has replaced older less specific drugs (e.g.

131 Studies of octreotide have not demonstrated a consistent benefit in

132 atostatin receptor scintigraphy, long-acting octreotide, hepatic artery embolization, endoscopic muco

133 SSTR subtypes that bind octreotide (ie, SSTR2, SSTR3, and SSTR5) were expressed

134 Octreotide improved control of esophageal variceal hemor

135 CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopath

136 imal PET/CT imaging results of (86)Y-CHX-A''-octreotide in a somatostatin receptor-positive tumor-bea

137 tudy was designed to investigate the role of octreotide in AKI after HIR.

138 performed with (125)I-JR11 and (125)I-Tyr(3)-octreotide in cancers from prostate, breast, colon, kidn

139 yristolated (1 muM) and in mice treated with octreotide in combination with sorafenib, the paradoxica

140 with that of the sst2 agonist (125)I-Tyr(3)-octreotide in large varieties of non-NET and NET.

141 ted States evaluated the use of prophylactic octreotide in patients undergoing pancreaticoduodenectom

142 tudy of the efficacy of pazopanib with depot octreotide in patients with advanced NETs.

143 tionale for assessing the potential value of octreotide in the treatment of PCLDs.

144 Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%)

145 rols, P = 0.63 CONCLUSIONS: Somatostatin and octreotide increase the likelihood of fistula closure.

146 Additionally, octreotide induced autophagy and autophagy inhibition wi

147 Octreotide induced sustained SSTR2A/beta-arrestin intera

148 t is a pathogenic factor in the formation of octreotide-induced gallstones.

149 In the paired studies, the octreotide-induced prolongation of LBTT caused an increa

150 The exact mechanism of octreotide-induced vasoconstriction remains unknown.

151 We found that somatostatin analogue octreotide induces apoptosis in VHL-HB stromal cells in

152 Assuming that chronic exposure to octreotide induces tachyphylaxis, we hypothesized that c

153 is interesting that in the WT preparations, octreotide inhibited both low- and high-threshold mechan

154 In vitro, octreotide inhibited cAMP levels by 35% and reduced cyst

155 rations in response to a 180-min infusion of octreotide, insulin, and glucose.

156 e therapy with antioestrogens and androgens, octreotide, interferon, and both arterial and systemic c

157 hat the antiangiogenic activity of NISAs and octreotide is mediated by an overall much less efficient

158 Octreotide is not indicated for prevention of diarrhea d

159 (111)In-Octreotide is used clinically to locate tumors overexpre

160 Somatostatin, but not octreotide, is likely to be effective in the prevention

161 on a per-lesion basis was 100%, for (111)In-octreotide it was 78.2%; specificity was not available).

162 SST-14, SST-28, and peptide analogs (octreotide, lanreotide, and vapreotide) stimulated clath

163 SSTR2A activated by SST-28, octreotide, lanreotide, or vapreotide was retained withi

164 nts were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizum

165 d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg every 28 days.

166 irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (expe

167 a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramu

168 ficantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuro

169 Coadministration of octreotide LAR and everolimus did not impact exposure to

170 domly assigned 42 patients in a 2:1 ratio to octreotide LAR depot (up to 40 mg every 28+/-5 days) or

171 Treatment with octreotide LAR did not prevent or reduce the severity of

172 This study could not prove the efficacy of octreotide LAR in the prevention of CID.

173 No benefit from octreotide LAR was identified in terms of need for diarr

174 nd safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this popula

175 aily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measu

176 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity.

177 the disease eventually becomes refractory to octreotide, leaving no proven treatment options.

178 n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45).

179 ty of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanc

180 y of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with

181 fusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered int

182 e upper normal limit) and had received 30 mg octreotide long-acting repeatable or 120 mg lanreotide (

183 In vivo, octreotide lowered cAMP content in cholangiocytes and se

184 arker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proli

185 f autophagy may be potentially linked to the octreotide mediated Akt/mTOR/p70S6K pathway deactivation

186 The combination of octreotide, midodrine, and albumin (triple therapy) is u

187 rs obtained from 10 octreotide-treated and 7 octreotide-naive patients.

188 All seven octreotide-naive tumors displayed exclusively nonphospho

189 e vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alone or in com

190 n; vasoconstrictor; terlipressin; midodrine; octreotide; noradrenaline; and norepinephrine.

191 hylenetriaminepentaacetic acid (DTPA)-D-Phe1-octreotide (OC) was developed for imaging somatostatin-r

192 retion may contribute to a variation in SSTR octreotide occupancy with a given dose among different p

193 ffect of GDNF was mimicked by the SOM analog octreotide (OCT) and required intact SOM neuronal pools.

194 In humans, the SOM stable analogue octreotide (OCT) is used to treat opioid-resistant pain.

195 To this end, the SST analogue octreotide (OCT) was microinjected into the striatum pri

196 [kg x min]) followed by 3-h infusion of GCG, octreotide (OCT), and insulin (INS) for basal replacemen

197 hitosan (CMCS) on inhibition of acylation of octreotide (Oct), salmon calcitonin (sCT), and human par

198 argeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferential

199 e efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in

200 (odds ratio 1.49 per point, P < 0.00001) and octreotide (odds ratio 3.30, P < 0.00001).

201 Effects of octreotide on cAMP levels and cyst expansion were studie

202 The effects of octreotide on hepatic and renal cystogenesis were invest

203 In calendar year 1996, 288 patients received octreotide on the surgical service at the authors' insti

204 (AAVP) vector displaying biologically active octreotide on the viral surface for ligand-directed deli

205 e shown a complex mechanism of the effect of octreotide on tumors.

206 The effect of octreotide on vascular tone in the superior mesenteric a

207 sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y-

208 diagnostic accuracy of (68)Ga-DOTATATE with octreotide or conventional imaging for pulmonary or gast

209 ys for 24 weeks, or continued treatment with octreotide or lanreotide (active control).

210 stratified according to previous treatment (octreotide or lanreotide) and growth hormone concentrati

211 acting release compared with active control (octreotide or lanreotide) in patients with inadequately

212 icacy compared with continued treatment with octreotide or lanreotide, and could become the new stand

213 the first-generation somatostatin analogues octreotide or lanreotide.

214 d by incubating peptide solutions of 0.2-4mM octreotide or leuprolide acetate salts in a 0.1M HEPES b

215 ale Sprague-Dawley rats were pretreated with octreotide or octreotide combined with 3-methyladenine (

216 ive agonist at lower concentrations than for octreotide or somatostatin-28, whereas SST5 did not inte

217 the use of terlipressin over midodrine plus octreotide (OR 26.25, 95% CI 3.07-224.21) to reverse hep

218 kephalin](OTf)(2) and [(eta(6)-Cp*Rh-Tyr(3))-octreotide](OTf)(2).

219 These results favor octreotide over vasopressin/terlipressin in the control

220 Use of octreotide (p<0.0001) and chemotherapy (p=0.003) were mo

221 hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar).

222 ributes of AAVP-TNF particles displaying the octreotide peptide motif (termed Oct-AAVP-TNF) were conf

223 TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group).

224 nificantly more effective than midodrine and octreotide plus albumin in improving renal function in p

225 rlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of HRS in a ran

226 /- 0.8 mmol/l) (P < 0.001) at 180 min during octreotide plus glucagon in doses of 0.5, 1.0, and 2.0 n

227 es with octreotide alone; the remainder with octreotide plus prednisone).

228 /- 0.1 mmol/l) (P < 0.001) at 180 min during octreotide plus saline and were 104 +/- 16 mg/dl (5.8 +/

229 However, whether octreotide preconditioning could also reduce acute kidne

230 Octreotide pretreatment significantly preserved renal fu

231 Twelve patients (24%) who received secondary octreotide prophylaxis developed another GI bleed, where

232 midgut NETs with long-acting and repeatable octreotide, PRRT reduced the hazard of disease progressi

233 Our results indicate that octreotide reduced renal injury after HIR due to its ind

234 In vivo blocking studies with octreotide reduced tumor uptake of (64)Cu-MMC(IR800)-TOC

235 servative therapy with diet modification and octreotide remain the standard initial approach.

236 obacter felis for 2 mo with the SOM analogue octreotide resolved the inflammation.

237 32%, 45%, 21%, and 2% of patients receiving octreotide, respectively, and in 51%, 24%, 21%, and 5% o

238 le symptomatic suprasellar hemangioblastoma, octreotide resulted in tumor volume reduction, symptom s

239 e and after receiving long-acting repeatable octreotide (Sandostatin LAR) were included in the study.

240 usive histology; three patients had negative octreotide scan).

241 radiotherapy, uptake on the [(111)In-DTPA(0)]octreotide scan, tumor load, grade 3-4 hematologic toxic

242 e alone has modest activity in patients with octreotide scan-positive thymoma.

243 , SSTR PET/CT was performed after an (111)In-Octreotide scan.

244 PET/CT even when performed after an (111)In-Octreotide scan.

245 Octreotide scanning has a sensitivity of primary tumor d

246 -diethylenetriaminepentaacetic acid-D-Phe(1)-octreotide scanning, a glomerular filtration rate of 80

247 d (111)In-diethylenetriaminepentaacetic acid-octreotide scans have greatly increased the sensitivity

248 significantly more lesions than (111)In-DTPA-octreotide scintigraphy (P < 0.001).

249 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicin

250 or weakly positive findings on (111)In-DTPA-octreotide scintigraphy to determine whether (68)Ga-DOTA

251 and 16 equivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE PET.

252 Short term and long term therapy with octreotide significantly improves survival and reduces t

253 In the unpaired and paired studies, octreotide significantly prolonged MCTT and LBTT.

254 In summary, octreotide slowed the progressive increase in liver volu

255 (90)Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical curr

256 tases that were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) befo

257 among (99m)Tc-hydrazinonicotinamide (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) S

258 Paired, before and during octreotide, studies were performed in 5 acromegalics.

259 ximum of 12.5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 mug thrice d

260 hase III studies, including those evaluating octreotide, sunitinib, and everolimus, has demonstrated

261 in antagonist) are based on the structure of octreotide that binds to three somatostatin receptor sub

262 ials from Europe have evaluated prophylactic octreotide (the long-acting synthetic analog of native s

263 Although symptom relief is available with octreotide, the disease eventually becomes refractory to

264 Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 1

265 gested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fr

266 are currently lacking to optimize dosing of octreotide therapy on an individual basis.

267 ay occur occasionally in patients on chronic octreotide therapy.

268 einuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12

269 gut hormone response that was attenuated by octreotide, thus identifying a potential therapeutic tar

270 lthough one patient required a small dose of octreotide to maintain normoglycemia.

271 e II) clinical trials, none of whom received octreotide, to provide a context for the bleeding rates.

272 itive neuroendocrine tumors obtained from 10 octreotide-treated and 7 octreotide-naive patients.

273 In contrast, 9 of the 10 octreotide-treated tumors contained phosphorylated sst2

274 Long-acting octreotide treatment diminished (68)Ga-DOTATATE uptake i

275 Octreotide treatment of human embryo kinase-sst2 cells i

276 In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression

277 Furthermore, during octreotide treatment, the mean conversion of 13C-CA to 1

278 ine the optimal dose, route, and duration of octreotide treatment.

279 in each organ were compared before and after octreotide treatment.

280 be octreotide as an effective treatment, and octreotide usage is increasing around the world for pati

281 Some authors have suggested that chronic octreotide use enhances the efficiency of radiolabeled s

282 scenarios of acute (24 h) and chronic (2 wk) octreotide use, followed by either nuclear imaging expos

283 In an animal model, SSTR occupancy by octreotide was assessed quantitatively with (68)Ga-DOTAT

284 he Cp*Rh moiety on the structure of [Tyr(3)]-octreotide was characterized by 2D NMR, resulting in the

285 and Drug Administration-approved indium 111 octreotide was followed by gamma camera imaging (planar

286 din or 4,5,6,7-tetrabromobenzotriazole, with octreotide was injected intraperitoneally from postnatal

287 Commercially obtained octreotide was modified at its N-terminus by this reagen

288 ion of alpha1-adrenergic vasoconstriction by octreotide was significantly enhanced by nitric oxide in

289 Octreotide was well tolerated; treated individuals repor

290 Trough concentrations of everolimus and octreotide were assessed.

291 sponses and calorie intake postsaline versus octreotide were compared between experimental and contro

292 stics of patients who rebled after receiving octreotide were compared with non-rebleeders.

293 NISAs and the somatostatin peptide analogue octreotide were evaluated in vitro by chemotaxis, prolif

294 Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatme

295 e of MIBG (which is a false transmitter) and octreotide (which is a ligand for G protein receptor) in

296 able, as in the United States, midodrine and octreotide with albumin are used as an alternative treat

297 albumin are both superior to midodrine plus octreotide with albumin for reversal of hepatorenal synd

298 in transfected cells incubated with (111)In-octreotide with and without somatostatin-28.

299 ugh the direct synthesis of the peptide drug octreotide with excellent yield and purity.

300 of sst subtype 2 (sst2)-expressing cells to octreotide would downregulate binding of 111In-pentetreo